Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Entrectinib, sold under the brand name Rozlytrek, is an anti-cancer medication used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. It is a selective tyrosine kinase inhibitor (TKI), of the tropomyosin receptor kinases (TRK) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK).
History, Community, Culture & Applications
Explore the main themes, entities and connections around Entrectinib. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
cancer ros1 kinase ntrk tyrosine solid cell drug tumors inhibitor alk approved treatment lung receptor side effects nsclc patients gene
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Entrectinib | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Entrectinib | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Entrectinib | ATC code | L01EX14 (WHO) | 1.00 | infobox |
| Entrectinib | CAS Number | 1108743-60-7 | 1.00 | infobox |
| Entrectinib | ChEBI | CHEBI:195558 | 1.00 | infobox |
| Entrectinib | ChEMBL | ChEMBL1983268 | 1.00 | infobox |
| Entrectinib | ChemSpider | 24808589 | 1.00 | infobox |
| Entrectinib | CompTox Dashboard (EPA) | DTXSID101026450 | 1.00 | infobox |
| Entrectinib | Drug class | Antineoplastic agent | 1.00 | infobox |
| Entrectinib | DrugBank | DB11986 | 1.00 | infobox |
| Entrectinib | Formula | C31H34F2N6O2 | 1.00 | infobox |
| Entrectinib | KEGG | D10926 | 1.00 | infobox |
| Entrectinib | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Entrectinib | Legal status | CA: ℞-only | 1.00 | infobox |
| Entrectinib | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Entrectinib | Legal status | US: ℞-only | 1.00 | infobox |
| Entrectinib | Legal status | EU: Rx-only | 1.00 | infobox |
| Entrectinib | License data | US DailyMed: Entrectinib | 1.00 | infobox |
| Entrectinib | MedlinePlus | a619049 | 1.00 | infobox |
| Entrectinib | Molar mass | 560.650 g·mol−1 | 1.00 | infobox |
| Entrectinib | Other names | RXDX-101, NMS-E628 | 1.00 | infobox |
| Entrectinib | Pregnancy category | AU: D | 1.00 | infobox |
| Entrectinib | PubChem CID | 25141092 | 1.00 | infobox |
| Entrectinib | PubChem SID | 347828307 | 1.00 | infobox |
| Entrectinib | Routes of administration | By mouth | 1.00 | infobox |
| Entrectinib | Trade names | Rozlytrek | 1.00 | infobox |
| Entrectinib | UNII | L5ORF0AN1I | 1.00 | infobox |
| Entrectinib | is a | selective tyrosine kinase inhibitor with specificity | 0.90 | text |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.